Neurocords
Spinal Cord Treatment Technology
Company Overview
Snapshot
Founded in March 2018, Neurocords specializes in regenerative therapies for spinal cord injuries. The company was acquired by Orgenesis in March 2025, marking a significant milestone in its development.
Business overview
Neurocords is focused on developing regenerative therapies for spinal cord injuries, leveraging a novel cellular therapy platform. The company aims to restore function following spinal cord injuries, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology.
Strategic signal
In March 2025, Orgenesis Inc. announced the acquisition of certain Neurocords LLC assets. This strategic move strengthens Orgenesis's regenerative medicine portfolio with advanced spinal cord injury therapies, signaling a validation of Neurocords' technology and its potential impact on the treatment landscape for spinal cord injuries.
Company Intelligence Q&A
- What is Neurocords' primary focus?
- Neurocords is developing regenerative therapies for spinal cord injuries, utilizing a novel cellular therapy platform aimed at restoring function.
- When was Neurocords founded?
- Neurocords was founded in March 2018.
- What was a significant recent event for Neurocords?
- In March 2025, Neurocords was acquired by Orgenesis, which integrated Neurocords' assets into its regenerative medicine portfolio.
- Which sector does Neurocords operate in?
- Neurocords operates within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology.
- What is the strategic impact of the acquisition by Orgenesis?
- The acquisition by Orgenesis in March 2025 strengthens Orgenesis's regenerative medicine portfolio by adding Neurocords' spinal cord injury therapies, indicating a strategic expansion in this therapeutic area.